VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2020

Feb 14, 2020

SEC Form 4/A — Form 4/A

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2020-02-05

Reporting Person: LEIDEN JEFFREY M (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-05	Common Stock	A	50566	$0.00	Acquired	156912	Direct
2020-02-05	Common Stock	A	28444	$0.00	Acquired	185356	Direct
2020-02-05	Common Stock	A	31462	$0.00	Acquired	216818	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	440	Indirect

Footnotes

F1: This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing.

F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020.

F3: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020.

F4: Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO.